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To evaluate the efficacy and toxicity of irinotecan (CPT-11) in combination with raltitrexed as first-line treatment of advanced
colorectal cancer (CRC). A total of 91 previously untreated patients with advanced CRC and measurable disease were enrolled in
this phase II study. The median age was 62 years (range 31–77); male/female 54/37; ECOG performance status was 0 in 50 patients
(55%), one in 39 (43%) and two in two (2%). Treatment consisted of CPT-11 350mgm
2 in a 30-min intravenous infusion on day 1,
followed after 30min by a 15-min infusion of raltitrexed 3mgm
2. Measurements of efficacy included the following: response rate,
time to disease progression and overall survival. Of the 83 evaluable patients valuable to objective response, there were five
complete responses (6%) and 23 partial responses (28%), for an overall response rate of 34% (95% CI: 25.9–46.5%). In all, 36
patients (43%) had stable disease, whereas 19 (23%) had a progression. The median time to progression was 11.1 months and the
median overall survival was 15.6 months. A total of 487 cycles of chemotherapy were delivered with a median of five per patient.
Grade 3–4 WHO toxicities were as follows: diarrhoea in 13 patients (15%), nausea/vomiting in four (4%), transaminase increase in
six (7%), stomatitis in two (2%), febrile neutropenia in three (3%), anaemia in five (6%) and asthenia in three (3%). The combination
CPT-11–raltitrexed is an effective, well-tolerated and convenient regimen as front-line treatment of advanced CRC.
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For more than 40 years, 5-fluorouracil (5FU) was the only
cytotoxic agent with significant activity in advanced colorectal
cancer (CRC). However, during the last decade, new cytotoxic
agents, such as the topoisomerase I inhibitor irinotecan (CPT-11)
or the platinum derivative oxaliplatin have demonstrated sig-
nificant single-agent activity in the setting of first- and second-line
chemotherapy. The value of the addition of CPT-11 to 5FU–LV, as
first-line treatment for metastatic CRC, has been established in two
large randomised trials (Douillard et al, 2000; Saltz et al, 2000).
These trials demonstrated that combination chemotherapy sig-
nificantly improved the response rate, median time to progression
and overall survival in patients with advanced CRC (Douillard et al,
2000; Saltz et al, 2000). Alternatively, the addition of oxaliplatin to
5FU–LV significantly improved the overall response rate and
median time to progression but not the median survival time
(Giacchetti et al, 2000; de Gramont et al, 2000).
Although combined therapy regimens are an important devel-
opment in the treatment of advanced CRC, they have a number of
disadvantages. On the one hand, there is an increased toxicity,
especially with the CPT-11–5FU–LV combination when 5FU is
administered as a bolus injection (Ledermann et al, 2001;
Rothenberg et al, 2001). On the other hand, these regimens
require either repeated in-hospital administration or the use of
infusion pumps, which may have a negative impact on the patient’s
quality of life. Accordingly, further investigation is needed into
new regimens that are less toxic and more convenient for patients,
while maintaining the same efficacy as the previous ones.
Raltitrexed is a specific inhibitor of thymidylate synthase. This
enzyme has a fundamental role in the de novo synthesis of the
nucleotide thymidine triphosphate, which is essential for DNA
synthesis. At a dose of 3mgm
2, it is active in a variety of tumours
such as breast, pancreatic or refractory ovarian cancers (Cunning-
ham et al, 1994), but it is in colorectal tumours where it shows the
best activity (Van Custem et al, 2002). Several phase III studies
performed in patients with advanced CRC demonstrated that
response rates and survival were similar to that of the combination
5FU–LV (Cunningham et al, 1995; Cocconi et al, 1998; Maughan
et al, 2002).
However, in another randomised trial, a survival advantage in
favour of patients treated with conventional 5FU–LV (Pazdur and
Vicent, 1997) was seen even when the response rate was similar.
The administration as a short 15-min intravenous infusion every 3
weeks adds value to the efficacy and toxicity profile of raltitrexed.
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lIn fact, in a study which compared the patients’ preferences
between raltitrexed and other 5FU-based regimens with regard to
side-effect attributes and administration attributes, 91% of the
patients expressed a preference for the former treatment (Young
et al, 1999).
CPT-11 and raltitrexed have different mechanisms of action and
experimental studies have shown a sequence-specific synergistic
cytotoxicity. Synergistic effects were demonstrated with a short-
term exposure to SN-38 (the CPT-11 active metabolite), followed
by raltitrexed. However, the reverse sequence, longer exposure or
co-exposure had an antagonistic effect (Aschele et al, 1998).
Accordingly, the CPT-11–raltitrexed combination is expected to
be at least as effective as the CPT-11–5FU–LV combination, but
more convenient and less toxic for the patient. A phase I study
with the combination CPT-11–raltitrexed demonstrated that this
regimen is active and associated with an acceptable toxicity. The
recommended dose for phase II studies was 350mgm
2 CPT-11
and3mgm
2 raltitrexed (Ford et al, 2000).
The purpose of this multicentre phase II study is to assess the
efficacy and safety of the CPT-11–raltitrexed combination as first-
line treatment in patients with advanced CRC.
PATIENTS AND METHODS
Patient population
From September 1999 to January 2001, 91 patients with recurrent
or metastatic CRC were included. They all had at least one lesion
histologically confirmed as adenocarcinoma. Patients who had
received prior adjuvant 5FU-based chemotherapy were eligible if
they had remained free of disease for at least 6 months after the
completion of adjuvant therapy. Patients with operable metastatic
disease were excluded from the study. Other inclusion criteria
were: (1) performance status p2, according to the Eastern
Cooperative Oncology Group (ECOG) scale; (2) life expectancy
of at least 3 months; (3) adequate haematological parameters (that
is a granulocyte count X210
9l
1 and platelets 410010
9l
1);
(4) adequate hepatic function, that is serum bilirubin o1.25 times
the upper normal limit, glutamic oxaloacetic transaminase values
(SGOT) and glutamic pyruvic transaminases (SGPT) o2.5 times
the upper normal limit in the absence of hepatic metastases or o5
times the upper normal limit in the presence of metastasis; (5)
adequate renal function, that is a serum creatinine value p1.25 times
the upper normal limit and creatinine clearance 465mlmin
1.
Patients with any prior chemotherapy for advanced disease,
brain or meningeal metastases, or a history of any other
malignancy, were excluded, except in cases of basal cell carcinoma
or in situ cervical carcinoma adequately treated. Patients provided
written informed consent according to directives of local ethical
committees.
All patients had measurable disease, as defined by the presence
of at least one bidimensionally measurable lesion by computed
tomography scan. Pleural effusion, ascites, osteoblastic lesions or
previously irradiated lesions were not accepted as measurable
disease. Patients who had received radiotherapy were eligible if
there was at least one measurable lesion outside the radiation field.
Treatment plan
The study regimen consisted of CPT-11 350mgm
2 in a 30-min
intravenous infusion on day 1, followed after 30min by a 15-min
infusion of raltitrexed 3mgm
2.
CPT-11 was administered according to the guidelines used for
CPT-11 monotherapy, including recommendations for using
atropine and loperamide. Routine antiemetic prophylaxis with a
5-hydroxytryptamine-3-receptor antagonist was used. Courses
were repeated every 21 days for a minimum of three per patient,
unless progressive disease was detected. Patients with partial
response or stable disease remained on chemotherapy until
progression or the appearance of unacceptable toxicity.
Patients were assessed for toxicity before each course and
graded according to standard WHO criteria (WHO, 1979).
Complete blood counts were obtained before the beginning of
each course. Therapy was delayed for 1 week if the neutrophil
count was o1.510
9l
1 or the platelet count o10010
9l
1 or
for significantly persisting non-haematological toxicity. Therapy
was definitely discontinued if toxicity persisted after a 2-week
delay. In case of grade 3 or 4 haematological toxicity, the dose of all
drugs was decreased by 25 or 50%, respectively. If grade 2 or 3
diarrhoea or stomatitis occurred, the dose was reduced by 25 or
50%, respectively; grade 4 diarrhoea or stomatitis led to treatment
withdrawal.
The Cockcroft–Gault formula (Cockcroft and Gault, 1976) was
used to calculate creatinine clearance before each cycle. If
creatinine clearance was between 55 and 65mlmin
1, the next
cycle was given 4 weeks later, and if it was between 25 and
54mlmin
1, the dose of raltitrexed was reduced by 50% and the
next cycle given 4 weeks later. If it was o25mlmin
1, the
treatment was interrupted.
Pretreatment and follow-up studies
Patients underwent the following baseline evaluations: full clinical
history, physical examination, performance status assessment,
haematological and biochemical profiles (including CEA level),
chest X-ray and computed tomography scan of the chest and
abdomen at baseline. Additional imaging investigations were
performed if clinically indicated. Computed tomography scan was
repeated every three courses to assess the objective response. At
the end of chemotherapy, all clinical, laboratory and imaging
studies were repeated and patients underwent follow-up examina-
tion every 2 or 3 months until death.
Toxicity and response criteria
Toxicity for each course was recorded and graded according to
WHO scales (WHO, 1979). For toxicity analysis, the worst data for
each patient across all courses were used. All patients who received
at least three cycles of therapy were considered for objective
tumour response. Response was evaluated by using the WHO
guidelines (WHO, 1979). All patients who receive at least one cycle
were evaluable to toxicity.
A complete response required the total disappearance of all
initially detected tumours in two observations not less than 4
weeks apart, with any evidence of new areas of malignant disease.
A partial response was defined as a reduction of at least 50% in the
sum of the products of the longest perpendicular diameter of all
clearly measurable tumour masses, in two observations not less
than 4 weeks apart, with no increase in the size of any lesion and
no evidence of new lesions. Stable disease was defined as a
decrease in total tumour size of less than 50% or a less than 25%
increase in any measurable lesion. Progression was defined as a
25% increase in the size of any lesion, the appearance of new areas
of malignant disease or performance status deterioration by more
than one level.
Time to tumour progression was estimated by the product limit
estimation from the date of the first course to the first evidence of
disease progression. Global survival was calculated by the same
method from the date of the first course until the date of death or
last known follow-up.
Statistical analysis
The primary end point was the response rate and the secondary
objectives were the clinical benefit, survival and time to
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lprogression. Dose intensity was calculated by dividing the total
mgm
2 of drug given by the number of weeks elapsed from the
beginning of therapy to the end of the last cycle.
The sample size was designed to reject a response rate of less
than 20%. According to the Fleming (1982) method, 19 patients
were first included.
Alternatively, a planned sample size of 90 evaluable patients was
chosen to better estimate the efficacy; 20% maximum width of the
95% confidence interval (CI) for an expected 35% overall response
rate.
Univariable analysis was used to compare the response rate,
survival and incidence of grade 3–4 toxicity between the different
groups formed according to age, gender, ECOG performance
status, adjuvant chemotherapy vs no adjuvant chemotherapy, liver
metastasis vs no liver metastasis and number of metastatic sites.
The Wilcoxon rank-sum test to compare the quantitative variables
and the exact Fisher test for the percentages were used. Survival
time and time to progression were calculated using the Kaplan–
Meier’s method. The Cox proportional hazard model was applied
to survival dates.
RESULTS
Patient characteristics
A total of 91 patients with recurrent or metastatic CRC were
entered into the study. The characteristics of these patients are
shown in Table 1. The median age of the series was 62 years (range
31–77). In all, 54 patients were males (59%) and 37 were females
(41%). There were 50 patients (55%) with ECOG-0 performance
status, 39 (43%) with ECOG-1 and two (2%) with ECOG-2. In 54
patients (59%), the primary tumour was located in the colon and
in 37 (41%) in the rectum. Synchronous metastatic disease was
observed in 47 patients (52%), in 22 of which (24%) the primary
tumour was not resected. Of the remaining patients, 44 (48%)
presented metastases secondary to a tumour previously removed.
Of these patients, 30 (33%) had previously received chemotherapy
as adjuvant and 14 (15%) had received chemotherapy and
radiotherapy. The liver was the predominant metastatic site
(71%), and the median number of involved sites was two per
patient.
A total of 487 cycles were given with a median of five cycles per
patient (range 1–14). In all, 16 patients (18%) received less than
three cycles of chemotherapy: eight (9%) due to a progression, four
(4%) due to the patient’s refusal, two (2%) moved to a different
city and two (2%) due to death apparently not related to the
neoplasia (one due to acute stroke and another due to acute
myocardial infarction). The last eight patients (9%) were not
evaluable for objective tumour response. In 12 patients (13%)
treatment had to be delayed on some occasions due to the
following reasons: an increase of transaminases in six, diarrhoea in
three, neutropenia in one and at the patient’s request in another
two. The median dose intensity of CPT-11 and raltitrexed was 115
and 0.98mgm
2week
1, respectively. A total of 85 patients (85%)
received 90% or more of the planned dose.
Second-line chemotherapy with oxaliplatin was given to 54% of
those patients who progressed or relapsed.
Tumour response and survival
Documented complete response was observed in five patients (6%)
and partial response in 23 (28%), for an overall response rate of
34% (95% confidence interval (CI) 25.9–46.5%). In addition, 36
patients (43%) remained with a stable disease and 19 (23%)
showed a progression (Table 2). The progression free survival was
11.1 months. The median survival was 15.6 months. The actuarial
1-year survival was 58%. No relationship between response rate
and site of metastases, number of metastatic sites, previous
adjuvant chemotherapy, ECOG performance status, age or sex was
observed. After analysing the relationship between these potential
prognostic factors and the progression-free time or survival, the
ECOG 0 patients were found to have a longer progression free time
than those with an ECOG 1–2 status (13.3 vs 7.9 months;
Po0.002). Similarly, a relationship between the ECOG perfor-
mance status and the overall survival was found (21.4 months for
ECOG 0 vs 8.3 months for ECOG 1–2; Po0.0001). The ECOG
performance status remained as the only survival-related variable
in the Cox multivariable regression model.
Toxicity
Treatment was well tolerated generally. In total, 64 patients (70%)
suffered some toxicity, usually grade 1–2. The main toxicities were
gastrointestinal and haematological. In all, 16 patients (18%)
developed grade 3–4 side effects (Table 3): 13 patients developed
diarrhoea (15%), four had nausea/vomiting (4%), six a transami-
nase increase (7%), two stomatitis (2%), three febrile neutropenia
(3%), five anaemia (6%) and three asthenia (3%). One patient
suffered an episode of atrial fibrillation during the fourth cycle,
which was terminated by using medical treatment. Four treatment-
related hospital admissions were reported and no toxic deaths
occurred. No relationships between the occurrence of grade 3–4
toxicity and the patient’s ECOG performance status, age or sex
were found.
Table 1 Patients characteristics
Characteristic No. (%)
Age (mean and range) 62 (31–77)
Sex
Male 54 (59%)
Female 37 (41%)
ECOG performance status
0 50 (55%)
1 39 (43%)
2 2 (2%)
Primary site
Colon 54 (59%)
Rectum 37 (41)
Metastasis sites
Liver 65 (71%)
Lung 29 (32%)
Local abdominal mass 23 (25%)
Others 22 (24%)
No. of metastatic sites
1 34 (37%)
2 25 (28%)
X3 32 (35%)
Adjuvant chemotherapy
Yes 44 (48%)
No 47 (52%)
Table 2 Therapeutic results in 83 patients
Results No. of patients (%)
Complete response 5 (6%)
Partial response 23 (28%)
Stable disease 36 (43%)
Progressive disease 19 (23%)
Overall response 34% (95% CI: 25.9–46.5%).
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The recent introduction of new drugs against advanced CRC with
distinct mechanisms of action has made it possible to achieve
better results than those obtained so far with the administration of
5FU–LV. The combination of CPT-11 with 5FU–LV has not only
led to a 15% increase in the response rate and a 3-month
prolongation in the median progression-free time with respect to
traditional 5FU–LV regimens, but has also resulted in a 2–3-
month increase of median survival (Douillard et al, 2000; Saltz et al,
2000). However, this modest although significant improvement has
been attained at the expense of increased toxicity. In fact,
approximately one fourth of the patients receiving these regimens
have grade 3–4 diarrhoea or grade 4 neutropenia (Douillard et al,
2000; Saltz et al, 2000). In addition, when administered as a bolus
injection together with CPT-11, 5FU–LV has been found to
increase the risk of toxic death associated with gastrointestinal
toxicity or thromboembolic disorders (Rothenberg et al, 2001). It
is thus necessary to explore other alternative regimens that are less
toxic and more convenient for the patient, while maintaining or
improving their efficacy. Our study should be considered from this
perspective.
The results obtained from our series (with an overall response
rate of 37%, a median progression-free time of 11.1 months and a
median survival of 15.6 months) suggest that the studied regimen
is effective for advanced CRC. Besides, its moderate toxicity, with
only 15% of patients having grade 3–4 diarrhoea and 3% of
patients with febril neutropenia, should be highlighted. These
results seem to be comparable to those found with regimens
combining 5FU–LV and CPT-11. However, given the lack of phase
III head-to-head comparative trials with these regimens, caution is
advised when making such comparisons, since differences may
exist between our patients’ characteristics and those of patients
included in the above series (Douillard et al, 2000; Saltz et al,
2000). So, while they are similar in age, ECOG performance status
and proportion of patients with liver metastases, some differences
may exist in the percentage of patients receiving adjuvant
chemotherapy (48% in our series vs 11% in the series of Saltz
et al). The proportion of patients with three or more metastatic
sites is also different (35% in our series vs 10% in the series of Saltz
et al vs 15% in that of Douillard et al (2000). The prognostic
relevance of this finding in patients with advanced CRC has
recently been underlined (Douillard et al, 2000; Ko ¨hne et al, 2002).
In spite of the good results achieved in our series, it should be
emphasised that the sequence that we used to administer the study
drugs might not have been the most appropriate. The findings
from in vitro studies suggest that the maximum synergism of
action is obtained when there is a 24-h interval between
administration of CPT-11 and raltitrexed (Aschele et al, 1998;
Jackman et al, 1999). However, we have followed the schedule
designed by Ford et al (2000) in which both drugs were given on
the same day. In agreement with these authors, we consider that
this administration approach could be more convenient for
patients. This same regimen has been used as second-line therapy
in a series of 52 patients with 5FU-resistant CRC, where a partial
response rate of 13.5% was obtained with moderate toxicity (grade
3–4 diarrhoea, 23%; grade 3–4 neutropenia, 17%) (Aparicio et al,
2003). Other authors, however, have investigated the activity and
tolerance of CPT-11 administration followed by raltitrexed 24h
later (Stevenson et al, 2001). In a phase II study including 46
patients, an overall response rate of 46% was achieved, with a
median overall survival of 57 weeks. These results were obtained at
the expense of a significant toxicity; grade 3–4 diarrhoea and
grade 3–4 neutropenia were present in 26 and 20% of patients,
respectively (Carnaghi et al, 2002). On the other hand, a phase I
study addressed a CPT-11 schedule (days 1 and 8) in combination
with raltitrexed (days 1 or 2) every 21 days. The CPT-11
recommended dose was 100 and 3mgm
2 for raltitrexed on day
1. However, when raltitrexed was administered on day 2, these
doses were not tolerated and a CPT-11 dose reduction to
75mgm
2 was necessary. Overall responses that reached 23% in
the 26 patients included were reported (Lewis et al, 2002).
Alternatively, the bi-weekly administration of CPT-11 and
raltitrexed has been examined in an attempt to increase the dose
intensity. In a phase I/II trial including 20 patients, a partial
response rate of 35% and a median survival of 13 months were
achieved (Colucci et al, 2001). Results obtained from these studies
appear similar to those found in our series; however, these
schedules may be more inconvenient for patients, since they need
to increase the number of hospital visits for treatment.
Other important issues to consider when assessing a che-
motherapy regimen are the patients’ preferences, the economic
cost and its potential impact on the quality of life. In this regard, a
study that analysed the patients’ preferences with respect to the
toxicity profile and the ease of administration showed that 91% of
patients preferred raltitrexed to other 5FU-based regimens, such as
those advocated by The Mayo Clinic, Gramont or Lokich (Young
et al, 1999). Furthermore, a study analysing the treatment-related
costs concluded that, although raltitrexed treatment-related costs
were high, they were compensated for when savings attributable to
its ease of administration were considered (Groener et al, 1999). Of
greater concern, however, are the results of a study that compared
the Lokich and Gramont regimens with raltitrexed.
Raltitrexed treatment was found to achieve comparable results
to those from the Lokich and Gramont regimens as for response
and survival rates, with costs that were similar to those from the
Lokich regimen and almost half those derived from the Gramont
regimen. Nevertheless, a greater toxicity, a lower quality of life in
comparison with other regimens and an increase of treatment-
related deaths were observed in raltitrexed-treated patients (Hale
et al, 2002; Maughan et al, 2002). In this regard, a special attention
is to be given to the patient’s renal function before each raltitrexed
Table 3 Toxicity per patient (WHO grades) during the whole trial
Toxicity
Per patient (89) Per cycle (487)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Anaemia 24 (27%) 5 (6%) 60 (12%) 7 (1%)
Thrombocytopenia 3 (3%) 3 (1%)
Nausea/vomiting 59 (66%) 3 (3%) 1 (1%) 184 (38%) 10 (2%) 3 (1%)
Diarrhoea 32 (36%) 10 (11%) 3 (3%) 94 (19%) 7 (1%) 6 (1%)
Stomatitis 6 (7%) 2 (2%) 8 (2%) 2 (1%)
Transaminases 26 (29%) 4 (4%) 2 (2%) 73 (15%) 7 (1%) 2 (1%)
Asthenia 27 (30%) 3 (3%) 109 (22%) 3 (1%)
Alopecia 31 (35%) 6 (7%) 3 (3%) 99 (20%) 14 (3%) 16 (3%)
Cholinergic syndrome 20 (22%) 44 (9%)
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(Jansman et al, 2000). In fact, raltitrexed AUC may even double
when creatinine clearance is lower than 65mlmin
1 (Judson et al,
1998). In the study by Hale et al, creatinine levels were not
regularly documented, although routine assessment of creatinine
clearance prior to each raltitrexed administration was specified in
the protocol (Cunningham et al, 2002). In addition to these
measures, it should be kept in mind that the prophylactic use of 5-
HT3 antagonists and dexamethasone reduces the incidence and
severity of nausea, diarrhoea, fever and asthenia associated with
the administration of raltitrexed (Thomas, 2000).
Thus, although all these data suggest that raltitrexed-
based combinations can improve the treatment acceptance
by the patients over other schedules requiring more frequent
hospital visits or the carrying of an infusion pump; further
investigation is needed to evaluate its impact on the patient’s
quality of life.
In conclusion, our study results suggest that the combination of
CPT-11 with raltitrexed is an active and moderately toxic
regimen for first-line treatment of the advanced CRC. Accordingly,
we reckon that it represents an attractive and convenient
alternative for the treatment of these patients. A large randomised
trial is needed to compare the efficacy of this regimen
with the standard combination of CPT-11/5FU–LV in patients
with advanced CRC.
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